Berkeley, United States
Kintsugi, founded in 2019 and based in the United States, is a pioneering company in the development of novel voice biomarker software aimed at detecting signs of depression and anxiety. As a leader in this innovative field, its mission is to broaden access to mental healthcare for all individuals. The company's technology is designed to analyze short speech clips, providing critical insights that help close mental health care gaps within risk-bearing health systems.
Kintsugi has been recognized for its groundbreaking efforts in artificial intelligence, making it to Forbes’ Top 50 AI companies to watch in 2022. This acknowledgment underscores its impact in the rapidly growing sectors of AI, Biotechnology, Health Care, and Machine Learning. Its most recent funding round, a $20.00M Series A investment on 28 February 2022, saw participation from notable investors like Acrew Capital, AngelList, Primetime Partners, and Insight Partners, among others. Kintsugi's technological advancements position it as a transformative force in digital mental health solutions.
